Journal article
Traceback: A proposed framework to increase identification and genetic counseling of BRCA1 and BRCA2 mutation carriers through family-based outreach
G Samimi, CF Caga-Anan, M Dean, LE Mechanic, LM Minasian, ME Sherman, LC Brody, MQ Bernardini, S Lheureux, PA Shaw, JS Kwon, IG Campbell, PA James, M Takenaka, DD Bowtell, G Chenevix-Trench, M Friedlander, SJ Ramus, FJ Couch, JA De Hullu Show all
Journal of Clinical Oncology | AMER SOC CLINICAL ONCOLOGY | Published : 2017
Abstract
In May 2016, the Division of Cancer Prevention and the Division of Cancer Control and Population Sciences, National Cancer Institute, convened a workshop to discuss a conceptual framework for identifying and genetically testing previously diagnosed but unreferred patients with ovarian cancer and other unrecognized BRCA1 or BRCA2 mutation carriers to improve the detection of families at risk for breast or ovarian cancer. The concept, designated Traceback, was prompted by the recognition that although BRCA1 and BRCA2 mutations are frequent in women with ovarian cancer, many such women have not been tested, especially if their diagnosis predated changes in testing guidelines. The failure to ide..
View full abstractGrants
Awarded by National Human Genome Research Institute
Funding Acknowledgements
Roche (I) AstraZeneca (Inst), Clovis Oncology (Inst), AbbVie (Inst), Pharmar (Inst) AstraZeneca (Inst), AbbVie (Inst), Myriad Genetics (Inst), Medivation (Inst) Roche (Inst), Genentech (Inst), AstraZeneca (Inst)